Fulvigen (Fulvestrant PFS) 250mg

Fulvigen (fulvestrant) 250mg PFS is an estrogen receptor antagonist used for hormone receptor-positive breast cancer treatment. This prefilled syringe formulation offers convenient administration for targeted therapy. Fulvigen belongs to the selective estrogen receptor degrader class.

Strength

250mg

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Glenmark Pharmaceuticals Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fulvigen 250mg PFS is used for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. It works by blocking estrogen receptors in cancer cells, slowing tumor growth. This medication is typically prescribed after other hormonal therapies have been tried. Fulvigen is also used in combination with other treatments for advanced breast cancer.

Side Effects

Fulvigen 250mg PFS may help reduce tumor size and slow cancer progression in eligible patients. Some individuals report improved quality of life during treatment. Common effects include injection site reactions and temporary hormonal changes. Patients may experience fatigue or gastrointestinal effects during therapy.

Precautions & Warnings

Store Fulvigen at room temperature away from light and moisture. Keep out of reach of children and pets. Handle the prefilled syringe carefully to avoid accidental needle sticks. Report any signs of infection, unusual bleeding, or severe reactions to your healthcare provider promptly.

Avoid Interactions

Fulvigen may interact with other hormonal medications or CYP3A4 inhibitors. Avoid grapefruit products as they can affect how Fulvigen works. Some herbal supplements may also interact with this medication. Always inform your doctor about all medications and supplements you're taking.

Frequently Asked Questions

Fulvigen 250mg PFS is used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women.

Fulvigen comes as a prefilled syringe for intramuscular injection, typically given by a healthcare professional.

Common effects include injection site reactions, fatigue, and temporary hormonal changes.

Fulvigen 250mg PFS is available through licensed pharmacies with a valid prescription.

Store Fulvigen at room temperature, away from light and moisture, and keep it out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.